Conclusions: NPTX2 emerges as a potential biomarker of treatment response to nusinersen in pwSMA suggesting its significant pathophysiological role in late-onset SMA, warranting further investigation. This evidence concerns the gene NPTX2 and proximal spinal muscular atrophy.